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Introduction: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically determined heart
disease characterized by ﬁbrofatty inﬁltrations in the myocardium, right and/or left ventricular involvement,
and ventricular tachyarrhythmias. Although ten genes have been associated with ARVC, only about 40% of
the patients have an identiﬁable disease-causing mutation. In the present study we aimed at investigating
the involvement of the genes SCN1B-SCN4B, FHL1, and LMNA in the pathogenesis of ARVC.
Methods: Sixty-ﬁve unrelated patients (55 fulﬁlling ARVC criteria and 10 borderline cases) were screened for
variants in SCN1B-4B, FHL1, and LMNA by direct sequencing and LightScanner melting curve analysis.
Results: A total of 28 sequence variants were identiﬁed: seven in SCN1B, three in SCN2B, two in SCN3B, two
in SCN4B, four in FHL1, and ten in LMNA. Three of the variants were novel. One of the variants was non-
synonymous. No disease-causing mutations were identiﬁed.
Conclusions: In our limited sized cohort the six studied candidate genes were not associated with ARVC.© 2012 Elsevier B.V.Open access under CC BY-NC-ND license. 1. Introduction
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an
inheritable cardiomyopathy pathologically characterized by ﬁbrofatty
inﬁltrations in the myocardium leading to thinning of the wall
and aneurysms. Clinical presentation is mainly due to ventricular
arrhythmias and may include palpitations, syncope, and sudden
cardiac death (Basso et al., 2009). Diagnosis is based on Task Force
criteria (Marcus et al., 2010), which encompass functional and ana-
tomical characteristics of the right ventricle, electrical abnormalities,
family history, and genetic information. The original Task Force criteria
were published in 1994, and in 2010 revised criteria were published
(Marcus et al., 2010).
To this date ARVC has been associated with mutations in ﬁve des-
mosomal (DSC2, DSG2, DSP, JUP, and PKP2) and ﬁve non-desmosomal
genes (TGFβ3, RYR2, TMEM43, DES, and TTN) (Basso et al., 2009; Taylor
et al., 2011; van Tintelen et al., 2009). Although ten genes have been
associated with ARVC, these only account for approximately 40% oflar Cardiology, Section 9312,
es vej 20, 2100 Copenhagen O,
(M.S. Olesen).
-NC-ND license. the patients with identiﬁable mutations (Christensen et al., 2010;
Bhuiyan et al., 2009) underlining the genetic heterogeneity of the
disease.
In the present study we aimed at investigating the involvement
of six candidate genes which have not previously been investigated
in the pathogenesis of ARVC: SCN1B-SCN4B (Sodium channel, voltage
gated, type I-IV, beta), encoding β-subunits for the cardiac sodium
channel, FHL1 (Four and a half LIM domains 1), encoding a member
of the four-and-a-half LIM only protein family, and LMNA (Lamin A/C),
encoding a nuclear envelope protein. All are highly expressed in
the heart and are known to interact with ARVC-associated genes.
They have also been associated with heritable arrhythmia syndromes
and/or cardiomyopathy (Brackenbury and Isom, 2008; Cowling et al.,
2011; Lu et al., 2011).
2. Methods
2.1. Study subjects
The study comprised 65 unrelated patients recruited from
Rigshospitalet, Copenhagen University Hospital, Denmark. All pa-
tients were of Northern European descent. The clinical characteristics
of the study population have previously been published (Christensen
et al., 2010). All patients have previously been screened for mutations
Table 1
Identiﬁed sequence variants.
Gene Variant Exon/intron Amino
acid
Minor
allele
MAFa dbSNP
SCN1B c.40+15G>T Intron T 0.238 rs72556351
c.448+181T>C Intron C 0.423 rs55742440
c.448+296C>A Intron A 0.169 rs67701503
c.448+301G>C Intron C 0.169 rs67486287
c.860T>C Exon p.I167I C 0.046 rs16969930
c.591-25T>G Intron G 0.008 rs28365107
c.591-14C>A Intron A 0.008 rs28365109
SCN2B c.70+32G>A Intron A 0.023 –
c.449-12C>A Intron A 0.454 rs8192613
c.648+38C>T Intron T 0.092 rs8192614
SCN3B c.438C>T Exon p.T146T T 0.054 rs1275085
c.445+37T>G Intron G 0.008 –
SCN4B c.174C>T Exon p.C58C T 0.046 rs45539032
c.639C>T Exon p.N213N T 0.023 rs72544155
FHL1 c.688+37G>A Intron A 0.008 –
c.689-8C>T Intron T 0.546 rs2076705
c.689-13C>T Intron C 0.031 rs11798700
c.823G>A Exon p.D275N A 0.008 –
LMNA c.612G>A Exon p.L204L A 0.015 rs12117552
c.369+56G>T Intron T 0.031 rs11264442
c.639+73C>T Intron T 0.031 rs11264443
c.640-52C>T Intron T 0.008 rs41314033
c.861T>C Exon p.A287A C 0.054 rs538089
c.937-83G>T Intron T 0.054 rs80356810
c.1157+16G>A Intron A 0.054 rs534807
c.1338T>C Exon p.D446D C 0.054 rs505058
c.1489-41C>T Intron T 0.054 rs553016
c.1698C>T Exon p.H566H T 0.231 rs4641
a Minor allele frequency in the 130 patient alleles tested.
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and TMEM43) and mutations were identiﬁed in 36% of patients ful-
ﬁlling the 1994 Task Force criteria (Christensen et al., 2010, 2011).
Since compound inheritance has been described (Bhuiyan et al., 2009)
we chose not to exclude patients with known mutations from further
screening. The study was approved by the local ethics committee,
followed the Helsinki II declaration, and all subjects gave written in-
formed consent before inclusion.
2.2. Genetic screening
Genomic DNA was isolated from blood samples using the QIAamp
DNA Blood Mini Kit (QIAGEN, Hilden, Germany). The coding
sequences and splice sites of SCN1B (NM_001037.3, NM_199037.2),
SCN2B (NM_004588.4), SCN3B (NM_018400.3), SCN4B (NM_174934.2),
FHL1 (NM_001449, NM_001159700, NM_001159704, NM_001167819,
NM_001159702, NM_001159703), and LMNA (NM_005572, NM_
0170707.2), corresponding to a total of 38 exons, were ampliﬁed
with intronic primers and bidirectionally sequenced using Big Dye
chain-termination chemistry (DNA analyzer 3730, Applied Biosystems,
CA, USA). Some amplicons were prescreened with a LightScanner
high-resolution melting curve analysis system (Idaho Technology, UT,
USA). All fragments with an abnormal melting proﬁle were sequenced.
Primers and PCR conditions are available on request.
3. Results
3.1. Study cohort
A total of 65 (38 men) patients were included in the study. 55 of
the patients fulﬁlled 1994 Task Force criteria for ARVC: ≥ two major
criteria (n=15), one major and ≥two minor criteria (n=36), and
four minor criteria (n=4). Ten patients had some ARVC characteris-
tics but did not fulﬁll the criteria: one major and one minor criterion
(n=5), three minor criteria (n=4), and two minor criteria (n=1).
3.2. Genetic screening
The variant analysis identiﬁed a total of 28 sequence variants:
Seven in SCN1B, three in SCN2B, two in SCN3B, two in SCN4B, four in
FHL1, and ten in LMNA. The identiﬁed variants are listed in Table 1.
Three of the variants were novel. All novel variants were positioned
in ﬂanking introns and did not affect a canonical splice site. One
non-synonymous variant was identiﬁed (FHL1 p.D275N). No disease-
causing mutations were identiﬁed.
4. Discussion
This study is the ﬁrst comprehensive attempt to associate ARVC
with genetic variation in the accessory subunits of the cardiac Nav1,5
channel, FHL1, and LMNA. Screening of these genes, representing 38
exons, revealed no disease-causing mutations and these genes are
therefore unlikely to be common causes of ARVC.
The channels carrying the cardiac sodium current (Nav1.5) is
composed of an α-subunit, encoded by SCN5A, and two of the four
β-subunits (Brackenbury and Isom, 2008). The β subunits (β1–β4),
encoded by SCN1B-4B, are multifunctional and members of the
immunoglobulin superfamily. Some of their functions may be inde-
pendent of the α-subunit (Brackenbury and Isom, 2008) and several
studies have demonstrated that β1 and β2 both play important
roles in homophilic and heterophilic cell adhesion and function as
cell adhesion molecules (Brackenbury and Isom, 2008; Chioni et al.,
2009). A recent study demonstrated a physical and functional inter-
action between Nav1.5 and the ARVC-associated gene PKP2 at the in-
tercalated disc and an altered sodium current after knockdown of
PKP2 (Sato et al., 2009). In addition, Deo et al. (2011) showed thatthese alterations of the sodium current complex lead to an increased
susceptibility to arrhythmias due to reentrant activity, even without
anatomical obstacles. Furthermore, it has been demonstrated that
16% of the ARVC patients exhibit inducible coved-type ST elevations
in right precordial leads (Peters, 2008), an ECG ﬁnding usually char-
acteristic of Brugada Syndrome, and that mutations affecting Nav1.5
are prevalent in Brugada syndrome patients with structural heart
abnormalities resembling ARVC (Frustaci et al., 2005; Frigo et al.,
2007). Both SCN1B and SCN3B have recently been associated with
Brugada Syndrome (Olesen et al., 2012). These ﬁndings thus suggest
that the sodium current complex could play a role in the pathogenesis
of ARVC. A variety of other diseases have also been associated with
mutations in SCN1B-4B, including cardiac arrhythmia, cancer, and
neurological diseases (Brackenbury and Isom, 2008; Chioni et al.,
2009; Olesen et al., 2011).
The FHL1 gene, located on the X chromosome, is characterized by a
half LIM domain in the N-terminus and four following complete LIM
domains. The protein is localized both in the cytosol and the nucleus
and has several functions including transcription regulation, cell sig-
naling, and sarcomere assembly (Cowling et al., 2011). FHL1 interacts
with TTN recently associated with ARVC4 (Taylor et al., 2011; Cowling
et al., 2011). A wide variety of human muscle diseases including
non-compaction, hypertrophic and dilated cardiomyopathies, have
been associated with FHL1 mutations (Cowling et al., 2011). In our
study the non-synonymous variant FHL1 p.D275N was present in one
patient. The variant affects an unconserved residue located in the
C-terminus of the FHL1 peptide. The variant has previously been
described in control populations (Schoser et al., 2009) and was present
in 31 out of 1669 alleles of American/European descent in the NHLBI
GO Exome Sequencing Project (Exome Variant Server). We therefore
consider it to be a polymorphism.
The LMNA gene, encoding the intermediate ﬁlament proteins
lamin A and C, plays a role in maintaining the structural integrity of
the inner nuclear membrane, in gene expression, and in organization
of chromatin (Lu et al., 2011). The lamins interact with several pro-
teins, including TMEM43, associated with ARVC5 (Basso et al., 2009;
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believed to cause dysregulation of the adipogenic pathway regulated
by PPAR-γ, resulting in adipogenesis, ﬁbrogenesis and myocyte
apoptosis (Merner et al., 2008), and may explain the ﬁbrofatty replace-
ment in the myocardium characteristic of ARVC. Also LMNA have
been suggested to affect PPAR-γ. (Capanni et al., 2005). Mutations in
LMNA have been associated with numerous extracardiac disorders,
conduction defects, ventricular arrhythmia, and dilated cardiomyopa-
thy (Lu et al., 2011). Dilated cardiomyopathy may mimic ARVC and
a predominantly left-sided form of ARVC is becoming increasingly
recognized (Sen-Chowdhry et al., 2008) making LMNA a plausible
candidate gene for ARVC.
This study has the following limitations: We only analyzed the
coding regions of SCN1B-4B, FHL1, and LMNA, and the possibility of
variants occurring in other regions of the genes cannot be excluded.
Our study cohort has a limited size and all patients were of Northern
European descent, thus we cannot exclude the possibility of different
results in cohorts of different ethnicity. The diagnosis of our cohort
is based on the 1994 Task Force criteria. We were not able to apply
the revised criteria published in 2010 to our cohort, due to lack of
necessary clinical data, e.g. all myocardial biopsies are obtained from
the septum.
In conclusion, we found no disease-causing mutations in ARVC pa-
tients within the SCN1B-4B, FHL1, and LMNA genes. The present study
is to our knowledge the ﬁrst attempt to associate genetic variation in
these genes with ARVC. Our results indicate that these six genes are
not common causes of ARVC.
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